Your Health, We Care
Cabozantinib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).
Cabozantinib, in combination with nivolumab, is indicated for the first-line treatment of patients with advanced RCC.
Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Cabozantinib is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
from FDA，2023.09
Cabozantinib is a non-chemotherapy prescription medication classified as a tyrosine kinase inhibitor···【more】
Recommended：3882026-05-02
This article is the package insert for Cabozantinib (LuciCaboz) tablets. Do not substitute Cabozantinib capsules for Cabozantinib tablets. If you encounter any problems, please con···【more】
Article source：Lucius LaosRelease date：2026-10-23Recommended：94
Cabozantinib (LuciCaboz), tablets 20mg. Date of first US approval: 2012.IndicationsCabozantinib (LuciCaboz) is a kinase inhibitor indicated for the treatment of: advanced renal cel···【more】
Article source：Lucius LaosRelease date：2026-10-23Recommended：91
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑specific tyrosine kinase inhibitor that exerts antitumor activity by selectively inhibiting the MET, VEG···【more】
Article source：Lucius LaosRelease date：2026-03-20Recommended：283
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) for the treatment of two patient populations:Adul···【more】
Article source：Lucius LaosRelease date：2026-03-20Recommended：319
Cabozantinib is a non-chemotherapy prescription medication classified as a tyrosine kinase inhibitor (TKI). It is administered as a tablet, taken once daily, or as directed by a he···【more】
Article source：Lucius LaosRelease date：2026-02-05Recommended：388
Cabozantinib has been approved for the treatment of various cancers.【more】
Article source：Lucius LaosRelease date：2026-01-06Recommended：282
Cabozantinib is a multi-kinase inhibitor that has demonstrated significant efficacy in the treatment of a variety of tumors. Knowing its recommended dosage is essential to ensure t···【more】
Article source：Lucius LaosRelease date：2025-02-17Recommended：483
Cabozantinib is a multi-targeted tyrosine kinase inhibitor with a wide range of indications in clinical applications.What are the suitable populations for cabozantinib?Cabozantinib···【more】
Article source：Lucius LaosRelease date：2025-02-17Recommended：479
Cabozantinib is a multi-targeted tyrosine kinase inhibitor that plays an important role in the treatment of a variety of diseases.What diseases is cabozozantinib suitable for?Cabob···【more】
Article source：Lucius LaosRelease date：2025-02-13Recommended：493
Cabotinib is a multi-targeted tyrosine kinase inhibitor that has shown broad potential for use in the medical field.What are the indications for cabozantinibCabozozantinib is appro···【more】
Article source：Lucius LaosRelease date：2025-02-13Recommended：511
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
